IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Saroja Pharma Industries India IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Mumbai and caters to Chemical - Speciality sector. Swastika Investmart is the merchant banker of Saroja Pharma Industries India IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 15th June 2023.
Saroja Pharma Industries India IPO posted revenues of Rs 50.35 crores and PAT of Rs 1.06 crores in FY25 on annualised basis.Financial results of Saroja Pharma Industries India IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Saroja Pharma Industries India IPO PAT Margin is 2.11%, ROCE (Return on Capital Employed) is 0.25% as per latest financial. The below table shows Saroja Pharma Industries India IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Saroja Pharma Industries India IPO is Rs 33.77 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Saroja Pharma Industries India IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Saroja Pharma Industries India IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Saroja Pharma Industries India IPO is ₹33.77 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Saroja Pharma Industries India IPO has a Price-to-Earnings (PE) ratio of 23.27 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Saroja Pharma Industries India IPO reported revenue of ₹50.35 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Saroja Pharma Industries India IPO provide insights into sales growth, market demand, and business scalability.
Saroja Pharma Industries India recorded an EBITDA of ₹ 2.88 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Saroja Pharma Industries India Profit After Tax (PAT) is ₹1.06 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 50.35 Cr.
EBITDA Margin:
5.72
%
Net Worth: ₹ 5.09 Cr.
Market Capitalisation:
₹ 33.77 Cr.
P/E:
23.27 times
P/BV: 2.38 times
EV/EBITDA: 15.14 times
Saroja Pharma Industries India operates in Chemical - Speciality and Pharmaceutical And Healthcare. The Issue is listed on NSE EMERGE in Sep, 2023. Saroja Pharma Industries India IPO size was 9.11 with Issue price of 84.00 .
Merchant Banker(s) of Saroja Pharma Industries India IPO: Swastika Investmart Limited
Saroja Pharma Industries India IPO subscription was 8.88 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Saroja Pharma Industries India IPO listed at a listing price of 68.25 against the offer price of 84.00.
The current market price of Saroja Pharma Industries India is 45.50.
Why Us?
